Andreessen Horowitz, Flare back weight-loss provider
Knownwell, a hybrid primary care and metabolic health company, raised $20 million in a Series A funding round led by venture capital firm Andreessen Horowitz.
Venture capital company Flare Capital Partners also participated in the round.
Read more: Why more doctors are seeking obesity certification
Knownwell said it would use the funding to expand its telehealth offering and incorporate patient satisfaction, asynchronous communication and provider workflow enablement tools into its care model.
The company, which launched in January, has raised $24.5 million, including this latest round. It prescribes glucagon-like peptide-1, or GLP-1, agonist medications. It also aims to promote a long-term approach to weight loss with nutritional counseling and behavioral health services.
The company additionally announced a clinical offering focused on teens living with obesity. It has one in-person clinic in Needham, Massachusetts, but it plans to open more locations.
Employer Direct Healthcare valued at $1B after $92M investment
Employer Direct Healthcare, a specialty healthcare network that connects patients with providers, is now valued at $1 billion following a $92 million investment from Insight Partners, a global technology investor. Read more here.
ImpriMed gets $23M from SoftBank Ventures Asia, others
ImpriMed, a precision medicine startup, raised $23 million in a Series A funding round.
The round was led by Seoul, South Korea-based investor Softbank Ventures Asia, with participation from HRZ Han River Partners, SK Telecom, KDB Silicon Valley, Ignite Innovation Fund, Samyang Chemical Group, Murex Partners and Byucksan.
ImpriMed has developed drug response prediction technology that has been primarily used for veterinary medicine. The technology uses artificial intelligence-based analysis of canine and feline cancer cells to make personalized drug response predictions.
With this latest round, the company will expand into human oncology while increasing headcount and broadening its research and development pipeline, according to a news release. ImpriMed is aiming to commercialize its multiple myeloma prognosis and drug response prediction software in the United States by 2025.
Remote monitoring company nabs $3.5M
Biorithm, which has developed a remote monitoring device for pregnant patients, raised $3.5 million in a Series A funding round.
The round was co-led by two Singapore-based venture capital firms, Adaptive Capital Partners and SEEDS Capital.
Biorithm's Femom technology combines remote monitoring data with personalized guidance and predictive analytics, with the aim of helping to identify early signs of pregnancy complications.
Biorithm said in a news release it will fund its expansion into Southeast Asia and the U.S. It will look to complete clinical studies to support a 510(K) premarket submission to the Food and Drug Administration.
Certainly Health raises $2.3M
Certainly Health, a healthcare marketplace application for booking medical and cosmetic care, raised $2.3 million in a funding round led by Pacific 8 Ventures, Y-Combinator and other investors.
The funding will allow the company to expand its team and improve its product offerings, according to a news release.
Certainly offers a marketplace for patients to book doctors with insurance with the goal of avoiding surprise bills. Patients enter insurance information and the reason for their visit reason and the company’s technology will predict out-of-pocket costs.
